BACKGROUND: We reviewed previous studies comparing schizophrenia patients and healthy subjects for performance on the Iowa Gambling Task (IGT) (a laboratory task designed to measure emotion-based decision-making), and found mixed results. We hypothesize that deficits in IGT performance in schizophrenia may be more specifically related to concurrent substance use disorders. To test this hypothesis, we compared schizophrenia patients with (SCZ((+))) or without (SCZ((-))) cannabis use disorders, to healthy subjects, on measures of cognition and IGT performance. METHODS: A comprehensive battery of cognitive tests and the IGT were administered to three groups of subjects: (1) 13 subjects with DSM-IV diagnosis of schizophrenia and no concurrent substance use disorders (mean age: 28+/-12 (SD); 54% males); (2) 14 subjects with schizophrenia and concurrent cannabis use disorders (mean age: 29+/-9 (SD); 71% males); and (3) 20 healthy subjects (mean age 33+/-10 (SD); 60% males). RESULTS: Compared to the healthy group, both schizophrenia groups were cognitively more impaired, and did worse on IGT performance. There were no differences between SCZ((+)) and SCZ((-)) patients on most of the cognitive tests, and IGT performance. CONCLUSIONS: Schizophrenia patients show widespread impairments in several cognitive domains and emotion-based decision-making. These results are consistent with the evidence that schizophrenia reflects a dorsolateral and orbitofrontal/ventromedial prefrontal cortex dysfunction. More intriguing, it appears that the concurrent abuse of cannabis has no compounding effects on cognition, as well as emotion/affect-based decision-making.
BACKGROUND: We reviewed previous studies comparing schizophreniapatients and healthy subjects for performance on the Iowa Gambling Task (IGT) (a laboratory task designed to measure emotion-based decision-making), and found mixed results. We hypothesize that deficits in IGT performance in schizophrenia may be more specifically related to concurrent substance use disorders. To test this hypothesis, we compared schizophreniapatients with (SCZ((+))) or without (SCZ((-))) cannabis use disorders, to healthy subjects, on measures of cognition and IGT performance. METHODS: A comprehensive battery of cognitive tests and the IGT were administered to three groups of subjects: (1) 13 subjects with DSM-IV diagnosis of schizophrenia and no concurrent substance use disorders (mean age: 28+/-12 (SD); 54% males); (2) 14 subjects with schizophrenia and concurrent cannabis use disorders (mean age: 29+/-9 (SD); 71% males); and (3) 20 healthy subjects (mean age 33+/-10 (SD); 60% males). RESULTS: Compared to the healthy group, both schizophrenia groups were cognitively more impaired, and did worse on IGT performance. There were no differences between SCZ((+)) and SCZ((-)) patients on most of the cognitive tests, and IGT performance. CONCLUSIONS:Schizophreniapatients show widespread impairments in several cognitive domains and emotion-based decision-making. These results are consistent with the evidence that schizophrenia reflects a dorsolateral and orbitofrontal/ventromedial prefrontal cortex dysfunction. More intriguing, it appears that the concurrent abuse of cannabis has no compounding effects on cognition, as well as emotion/affect-based decision-making.
Authors: Tony P George; Jennifer C Vessicchio; Angelo Termine; Deanna M Sahady; Cory A Head; W Thomas Pepper; Thomas R Kosten; Bruce E Wexler Journal: Neuropsychopharmacology Date: 2002-01 Impact factor: 7.853
Authors: S Sevy; D G Robinson; S Holloway; J M Alvir; M G Woerner; R Bilder; R Goldman; J Lieberman; J Kane Journal: Acta Psychiatr Scand Date: 2001-11 Impact factor: 6.392
Authors: Richard J Beninger; James Wasserman; Katherine Zanibbi; Danielle Charbonneau; Jennifer Mangels; Bruce V Beninger Journal: Schizophr Res Date: 2003-06-01 Impact factor: 4.939
Authors: K I Bolla; D A Eldreth; E D London; K A Kiehl; M Mouratidis; C Contoreggi; J A Matochik; V Kurian; J L Cadet; A S Kimes; F R Funderburk; M Ernst Journal: Neuroimage Date: 2003-07 Impact factor: 6.556
Authors: Thilo van Eimeren; Ji H Ko; Giovanna Pellechia; Sang S Cho; Sylvain Houle; Antonio P Strafella Journal: Hum Brain Mapp Date: 2011-10-22 Impact factor: 5.038
Authors: Robert Miranda; James MacKillop; Lori A Meyerson; Alicia Justus; William R Lovallo Journal: Alcohol Clin Exp Res Date: 2009-03-06 Impact factor: 3.455